Perrigo Company plc
General ticker "PRGO" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.5B (TTM average)
Perrigo Company plc does not follow the US Stock Market performance with the rate: -23.7%.
Estimated limits based on current volatility of 4.9%: low 9.94$, high 10.96$
Factors to consider:
- Company pays dividends (quarterly): last record date 2026-05-29, amount 0.29$ (Y10.82%)
- Total employees count: 8100 (-3.3%) as of 2025
- US accounted for 60.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Market competition, Regulatory and compliance, Supply chain disruptions, Innovation challenges, Raw material costs
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.27$, 18.76$]
- 2026-12-31 to 2027-12-31 estimated range: [8.64$, 17.13$]
Financial Metrics affecting the PRGO estimates:
- Positive: with PPE of 5.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 6.62 < Operating cash flow per share per price, % of 12.63
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0.12 <= 0.28
- Negative: Investing cash flow per share per price, % of -3.99 <= -0.60
Short-term PRGO quotes
Long-term PRGO plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $4,654.80MM | $4,379.40MM | $4,253.10MM |
| Operating Expenses | $4,502.90MM | $4,266.50MM | $5,375.30MM |
| Operating Income | $151.90MM | $112.90MM | $-1,122.20MM |
| Non-Operating Income | $-160.20MM | $-193.60MM | $-175.70MM |
| Interest Expense | $173.80MM | $187.80MM | $162.50MM |
| R&D Expense | $122.50MM | $112.20MM | $95.40MM |
| Income(Loss) | $-8.30MM | $-80.70MM | $-1,297.90MM |
| Taxes | $-3.90MM | $80.00MM | $104.40MM |
| Other Income(Loss) | $-8.30MM | $-11.10MM | $-23.10MM |
| Net Income(Loss)* | $-12.70MM | $-171.80MM | $-1,425.40MM |
| Stockholders Equity | $4,767.90MM | $4,319.40MM | $2,935.50MM |
| Inventory | $1,140.90MM | $1,081.80MM | $1,149.00MM |
| Assets | $10,809.10MM | $9,647.70MM | $8,535.20MM |
| Operating Cash Flow | $405.50MM | $362.90MM | $238.50MM |
| Capital expenditure | $101.70MM | $118.30MM | $93.40MM |
| Investing Cash Flow | $-77.50MM | $78.80MM | $-75.40MM |
| Financing Cash Flow | $-187.20MM | $-611.00MM | $-220.50MM |
| Earnings Per Share** | $-0.09 | $-1.25 | $-10.29 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.